Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.

ABSTRACT: Prostate cancer is the most commonly diagnosed cancer affecting men in the United States. The prostate is a hormone-dependent gland in which androgen hormones testosterone and dihydrotestosterone bind to and activate the androgen receptor, initiating nuclear translocation of androgen receptor and a subsequent signaling cascade. Due to the androgen dependency of the prostate, androgen deprivation therapies have emerged as first line treatment for aggressive prostate cancer. Such therapies are effective until the point at which prostate cancer, through a variety of mechanisms including but not limited to generation of ligand-independent androgen receptor splice variants, or intratumoral androgen production, overcome hormone deprivation. These cancers are androgen ablation resistant, clinical

SUBMITTER: Rice MA 

PROVIDER: S-EPMC6723105 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature